Skip to main content

Sotagliflozin Cuts MACE Rate in Patients With T2DM, CKD, CVD Risk Factors

Medically reviewed by Carmen Pope, BPharm. Last updated on March 3, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, March 3, 2025 -- For patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors, the dual sodium-glucose co-transporter (SGLT)-1/2 inhibitor sotagliflozin is associated with a significantly reduced rate of major adverse cardiovascular events (MACE), with independent reductions in myocardial infarction and stroke, according to a study published online Feb. 14 in The Lancet Diabetes & Endocrinology.

Rahul Aggarwal, M.D., from Harvard Medical School in Boston, and colleagues conducted a prespecified secondary analysis of the SCORED trial, a double-blind, randomized trial enrolling adult patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors. A total of 10,584 patients from 750 sites in 44 countries were randomly assigned to receive oral sotagliflozin or placebo (5,292 to each group) between Dec. 8, 2017, and Jan. 20, 2020.

The researchers found that the rate of total MACE was significantly lower in the sotagliflozin group versus placebo group (4.8 versus 6.3 events per 100 person-years; hazard ratio [HR], 0.77). Among stratified subgroups, there was a consistent effect for sotagliflozin on total MACE, with no evidence of heterogeneity. Compared with placebo, sotagliflozin also significantly reduced the rate of myocardial infarction (1.8 versus 2.7 events per 100 person-years; HR, 0.68) and stroke (1.2 versus 1.8 events per 100 person-years; HR, 0.66).

"This ischemic benefit of sotagliflozin on both stroke and myocardial infarction has not been observed in trials of selective SGLT-2 inhibitors, warranting further investigation of SGLT-1 inhibition as a potential mechanism for these effects," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Lexicon Pharmaceuticals, which manufactures sotagliflozin and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted March 2025

Read this next

High-Volume Exercise Tied to Increased Coronary Artery Calcification Score

WEDNESDAY, May 28, 2025 -- Male athletes with high-volume exercise training have a higher burden of calcified plaque than male nonathletes, according to a review published in the...

Odds of Cardiovascular Events Up for RSV Hospitalization Versus COVID-19 Hospitalization

WEDNESDAY, May 28, 2025 -- Patients with respiratory syncytial virus (RSV) hospitalization have increased odds of any acute cardiovascular event compared with COVID-19...

Sedentary Behavior in U.S. Adults Declined in Last Decade

WEDNESDAY, May 28, 2025 -- Sedentary behavior among U.S. adults fell between 2013 and 2020 but plateaued after that, according to a research letter published online May 21 in...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.